JUN 01, 2017 4:21 PM PDT

A New Test to Measure if HIV Can Be "Cured"

WRITTEN BY: Kara Marker

When is someone “cured” of HIV? If there is such a state reachable with drug therapies, how can a doctor tell? The problem stems from HIV’s tendency to hide dormant inside of immune cells - CD4+ T cells specifically - that make remaining viruses leftover after antiviral treatment difficult to detect.

 

Dr. Anwesha Sanyal indicates HIV-infected cells collecting at the bottom of a vial being prepared for Pitt Public Health's TZA test. Credit: Tim Betler/UPMC

 

From the University of Pittsburgh Schools of the Health Sciences, researchers have published a new study in the journal Nature Medicine describing their new test design for detecting dormant HIV.

 

"Globally there are substantial efforts to cure people of HIV by finding ways to eradicate this latent reservoir of virus that stubbornly persists in patients, despite our best therapies," said senior author Phalguni Gupta, PhD. "But those efforts aren't going to progress if we don't have tests that are sensitive and practical enough to tell doctors if someone is truly cured."

 

The existing test most experts rely on is the “quantitative viral outgrowth assay” or “Q-VOA.” Its shortcomings? Q-VOA requires a large volume of blood, is labor-intensive, time-consuming, and expensive, and the estimate the test provides usually doesn’t tell the whole story.

 

The Pittsburgh researchers instead offer the new “TZA” test to detect dormant HIV, which improves upon virtually all of Q-VOA’s weaknesses. The test works by detecting activity of a unique gene that is only expressed when HIV is currently replicating. TZA produces results in one week - Q-VOA takes two - and is one-third of the cost of Q-VOA. TZA also requires a much smaller amount of blood for testing and is less labor-intensive.

Thanks to the new test, the Pittsburgh researchers discovered that the amount of dormant HIV existing in “nearly cured” people is 70 times as much as experts previously thought.

"Using this test, we demonstrated that asymptomatic patients on antiretroviral therapy carry a much larger HIV reservoir than previous estimates--as much as 70 times what the Q-VOA test was detecting," Gupta explained. "Because these tests have different ways to measure HIV that is capable of replicating, it is likely beneficial to have both available as scientists strive toward a cure."

 

The new TZA test could soon be the most commonly-used test to detect specific numbers of latent HIV in the body. With these measurements made, doctors can alter an HIV patient’s treatment plan to send them on a better, more specialized path to a true “cure.”

 

Source: University of Pittsburgh Schools of the Health Sciences

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 31, 2019
Immunology
AUG 31, 2019
AI Not Ready To Predict Acute Kidney Injury
An international group of scientists from the U.S. and U.K. published new research in Nature about the effectiveness of AI in predicting Acute Kidney Injur...
SEP 14, 2019
Genetics & Genomics
SEP 14, 2019
DNA Construction Kit Could Drive Down Costs of Immune Therapy
Researchers at KU Leuven in Belgium have created a DNA construction kit that, when injected into muscle cells, enables sheep to produce new antibodies to f...
NOV 22, 2019
Immunology
NOV 22, 2019
Rogue Inflammation Activates Depression During Pregnancy
Unresolved inflammation in a pregnant woman’s body can lead to serious depression during and after pregnancy. A new study investigates the physiologi...
DEC 04, 2019
Immunology
DEC 04, 2019
Predicting Death with Clinical Immune Indicators
Immune and inflammation status could help doctors predict which individuals are most at-risk for death. Results from a new study mark the first step toward...
DEC 10, 2019
Immunology
DEC 10, 2019
T Cell Subset Uniquely Equipped to Target IBD
A specialized form of T cell emerges as a new focus for gastrointestinal health research, specifically in the context of inflammatory bowel disease (IBD) f...
DEC 11, 2019
Drug Discovery & Development
DEC 11, 2019
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
Loading Comments...